{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:37:53Z","timestamp":1772249873818,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2680,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,3,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The eradication of <jats:italic>Helicobacter pylori<\/jats:italic> plays a pivotal role in the treatment of peptic ulcer disease. Metronidazole resistance, common in Iran, is claimed to be a major reason for the failure of metronidazole\u2010containing regimens. Both clarithromycin and furazolidone are potential alternatives for metronidazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To assess and compare the effectiveness of clarithromycin\u2010 and furazolidone\u2010based regimens in eradicating <jats:italic>H. pylori<\/jats:italic> in a population with a high metronidazole resistance rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with proven duodenal ulcer and <jats:italic>H.\u2003pylori<\/jats:italic> infection were randomly assigned to one of two groups. The patients received 2\u2003weeks of omeprazole 20\u2003mg b.d., amoxicillin 1000\u2003mg b.d, bismuth subcitrate 240\u2003mg b.d. and either clarithromycin 500\u2003mg b.d. (the OABC group) or furazolidone 200\u2003mg b.d. (the OABF group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A total of 118 patients were randomized, 55 in the OABC group and 63 in the OABF group. The intention\u2010to\u2010treat eradication rate was 84% and 85% for the OABF and OABC groups, respectively. The per protocol eradication rates were 90% for both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>OABC and OABF are both effective in eradicating <jats:italic>H. pylori<\/jats:italic> in areas where metronidazole resistance is a problem. OABF is a good alternative in the face of growing resistance to clarithromycin in developed countries, and is attractive for developing countries where clarithromycin is not readily available.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.00931.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:05Z","timestamp":1047354245000},"page":"411-416","source":"Crossref","is-referenced-by-count":69,"title":["Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of <i>Helicobacter<\/i> pylori in a population with a high metronidazole resistance rate"],"prefix":"10.1111","volume":"15","author":[{"given":"H.","family":"Fakheri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Merat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Khatibian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Z.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Massarrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic disease. NIH Consensus conference","volume":"272","author":"NIH Consensus development panel on Helicobacter pylori ulcer disease","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00673.x"},{"key":"e_1_2_6_4_2","first-page":"2025","article-title":"Helicobacter pylori recurrence after successful eradication: 5\u2010year follow\u2010up in the United States","volume":"92","author":"Abu\u2010Mahfouz MZ","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003399077"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2000.0050S1023.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00795.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003399013"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80692-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80861-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199810000-00006"},{"key":"e_1_2_6_12_2","first-page":"1419","article-title":"Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori and prevention of ulcer replace over a 1\u2003year follow\u2010up period: a prospective, randomized, controlled study","volume":"90","author":"Saber\u2010Firoozi M","year":"1995","journal-title":"Am J Gastroentrol"},{"key":"e_1_2_6_13_2","first-page":"A 2218","article-title":"Effect of two different doses of metronidazole and tetracycline in classic triple therapy on eradication of H. pylori and its metronidazole resistant strains","volume":"112","author":"Salman\u2010Raoghani H","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_14_2","first-page":"60","article-title":"Susceptibility of various strains of Helicobacter pylori to selected agents","volume":"3","author":"Siavoshi F","year":"2000","journal-title":"Arch Irn Med"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/22.5.631"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2000.00011.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2214-2216.2000"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00709.x"},{"key":"e_1_2_6_19_2","first-page":"A126","article-title":"Effect of furazolidone bismuth subcitrate and amoxicillin for eradication of Helicobacter pylori in Iran","volume":"112","author":"Malekzadeh R","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00640.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1046\/j.1365-2036.1999.00653.x","article-title":"Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer","volume":"13","author":"Dani R","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_22_2","first-page":"592","article-title":"Furazolidone, amoxicilline, bismuth triple therapy for Helicobacter pylori infection","volume":"11","author":"Segure AM","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_23_2","first-page":"1027","article-title":"Mini\u2010dose (1 micro\u2010ci) 14C urea breath test for detection of Helicobacter pylori","volume":"89","author":"Raju GS","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_6_25_2","first-page":"A14","article-title":"Effectiveness of H. pylori treatment regimens in clinical practice: a community based outcomes study","volume":"112","author":"Fennerty M","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.11.s1.11.x"},{"key":"e_1_2_6_27_2","first-page":"A105","article-title":"Metronidazole and clarithromycin resistance among HP isolates from a large hospital in the United State","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_28_2","first-page":"A 236","article-title":"Metronidazole resistance is high in Korea and Columbia and appears to be rapidly increasing in the U.S","volume":"110","author":"Reddy R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00170.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1996.03530320046033","article-title":"Consenses conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of American College of Gastroenterology","volume":"275","author":"Soll AH","year":"1996","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_31_2","first-page":"1203","article-title":"Clarithromycin, tetracycline, and bismuth: a new non\u2010metronidazole therapy for Helicobacter pylori infection","volume":"89","author":"Al\u2010Assi AT","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00776.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00767.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2000.tb00813.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92962-2"},{"key":"e_1_2_6_36_2","first-page":"271","article-title":"Elimination of Helicobacter pylori under treatment with omeprazole","volume":"28","author":"Stolte M","year":"1990","journal-title":"Gastroenterology"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.8.842"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80705-1"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00224.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199807000-00010"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.035_c.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.3.323"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091325"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1992.tb01034.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91653-8"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90324-1"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92639-5"},{"key":"e_1_2_6_48_2","unstructured":"GrahamDY KleinPD&OpekumAR et\u2003al.In vivosusceptibility ofCampylobacter pylori.Am J Gastroenterol1989;84:233\u20138;1996;110: A238\u2013A238(Abstract)."},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1637"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00219.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00602.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.4.477"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00931.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00931.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00931.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:44:10Z","timestamp":1697535850000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00931.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3,6]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00931.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00931.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3,6]]}}}